What is the recommended management of hyperpyrexia and hyperthermia in an adult patient?

Management of Hyperpyrexia and Hyperthermia in Adults

The management of hyperpyrexia and hyperthermia depends critically on the underlying mechanism: for malignant hyperthermia, immediately administer IV dantrolene 2-3 mg/kg and initiate aggressive cooling to target temperature <38.5°C; for non-anesthetic hyperthermia (heatstroke, drug-induced), prioritize rapid physical cooling with cold IV fluids and external cooling methods while treating the underlying cause. 1, 2

Immediate Recognition and Differentiation

The first critical step is distinguishing between true hyperthermia (failed thermoregulation) and hyperpyrexia (elevated set-point fever). This distinction determines your treatment approach:

• Hyperthermia: Thermoregulatory failure where physical cooling is essential and antipyretics are ineffective 3
• Hyperpyrexia: Regulated fever with elevated set-point where antipyretics may help but physical cooling triggers counterproductive vasoconstriction 4, 3

Malignant Hyperthermia Crisis Management

If the patient has recent anesthetic exposure (volatile agents or succinylcholine), treat as malignant hyperthermia immediately 1, 2:

Immediate Actions (within minutes):

• Stop all trigger agents and hyperventilate with 100% O₂ at 2-3 times normal minute volume
• Declare emergency and call for help
• Administer dantrolene 2-3 mg/kg IV immediately (mix 20 mg vials with 60 ml sterile water) 2
• Repeat dantrolene 1 mg/kg every 5 minutes until ETCO₂ <6 kPa and temperature <38.5°C
• Prepare for up to 36-50 ampoules needed; maximum 10 mg/kg dose may need to be exceeded 1, 2

Cooling Protocol:

• Infuse 2000-3000 ml chilled (4°C) 0.9% saline IV 1
• Apply wet cold sheets, fans, and ice packs to axillae and groin
• Stop cooling once temperature reaches <38.5°C to avoid overcorrection 1

Critical Monitoring:

• Establish wide-bore IV access, arterial line, central venous line, urinary catheter
• Monitor K⁺, CK, arterial blood gases, myoglobin, glucose, renal/hepatic function, coagulation
• Check for compartment syndrome
• Minimum 24-hour ICU/HDU monitoring required 1

Treat Complications:

• Hyperkalaemia: Dextrose 50% 50 ml with 50 IU insulin; CaCl₂ 0.1 mmol/kg IV; consider dialysis 1
• Acidosis: Hyperventilate to normocapnoea; sodium bicarbonate IV if pH <7.2 1
• Arrhythmias: Amiodarone 300 mg (3 mg/kg) IV; beta-blockers if tachycardia persists 1
• Maintain urine output >2 ml/kg/h: Furosemide 0.5-1 mg/kg, mannitol 1 g/kg, crystalloid fluids 1

Non-Anesthetic Hyperthermia (Heatstroke, Drug-Induced)

For hyperthermia without anesthetic triggers 5, 6, 7:

Cooling Strategy:

• Cold IV fluids (4°C) 2000-3000 ml as first-line intervention 5
• External cooling with ice water immersion (if young/healthy) or evaporative cooling (wet sheets + fans)
• Avoid tepid sponging and ice packs alone—these induce shivering and vasoconstriction 4
• Target temperature <38.5°C then stop to prevent overshoot

Drug-Induced Hyperthermia:

Identify the syndrome based on medication history 6, 7:

• Neuroleptic malignant syndrome: Stop antipsychotics, supportive care, consider bromocriptine 8
• Serotonin syndrome: Discontinue serotonergic agents, benzodiazepines for agitation, cyproheptadine if severe
• Anticholinergic toxicity: Physostigmine in selected cases
• Sympathomimetic toxicity: Benzodiazepines, avoid beta-blockers

All require immediate ICU admission, aggressive cooling, and treatment of rhabdomyolysis/multi-organ failure 7

Hemodynamic Support:

• Fluid resuscitation titrated to heart rate, urine output, blood pressure
• Invasive monitoring if hypotension persists after initial fluids and cooling 5
• Apply sepsis resuscitation principles given pathophysiological similarities 5

Critical Pitfalls to Avoid

• Never use antipyretics for true hyperthermia—they are ineffective and delay appropriate treatment 3
• Never use tepid sponging or ice packs alone—these trigger shivering and worsen outcomes 4
• Never delay dantrolene in suspected malignant hyperthermia—mortality increases dramatically with delayed treatment 1, 2
• Never assume infection—up to 50% of ICU fever is non-infectious; drug-induced causes must be excluded 9, 7
• Never overlook medication compliance—abrupt withdrawal of antiparkinsonian drugs can cause parkinsonism hyperpyrexia syndrome 8

Special Considerations

Neurologically impaired patients (spinal cord injury, intracranial pathology) may develop neurogenic fever requiring continuous temperature monitoring and aggressive management, as autonomic dysfunction can cause rapid biphasic temperature swings 10, 11. These patients warrant ICU-level care with heightened vigilance for life-threatening temperature extremes.